Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Silver

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Psychiatry Research|October 19, 2004
Brief emotion training improves recognition of facial emotions in chronic schizophrenia. A pilot studyHenry Silver, Craig Goodman, Gabriela Knoll, et al.
Comprehensive Psychiatry|September 24, 2005
Insight into illness in schizophreniaCraig Goodman, Gabriella Knoll, Victoria Isakov, et al.
Current Medicinal Chemistry|November 20, 2012
The role of GABA-A receptor in the synergism between SSRI and antipsychotic in schizophrenia; implications for antipsychotic modes of actionsHenry Silver, Reef Einoch, Moussa Youdim, et al.
Schizophrenia Research|April 17, 2002
Perception of happy and sad facial expressions in chronic schizophrenia: evidence for two evaluative systemsHenry Silver, Nili Shlomo, Travis Turner, et al.
The American Journal of Psychiatry|September 30, 2003
Working memory deficit as a core neuropsychological dysfunction in schizophreniaHenry Silver, Pablo Feldman, Warren Bilker, et al.
International Clinical Psychopharmacology|September 30, 2005
A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patientsHenry Silver, Craig Goodman, Victoria Isakov, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 27, 2008
Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?Henry Silver, Yael Chertkow, Orly Weinreb, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 31, 2007
Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamineYael Chertkow, Orly Weinreb, Moussa B H Youdim, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|July 7, 2009
Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophreniaYael Chertkow, Orly Weinreb, Moussa B H Youdim, et al.
The International Journal of Neuropsychopharmacology|February 26, 2010
The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatmentLena Danovich, Orly Weinreb, Moussa B H Youdim, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Psychiatry Research|October 19, 2004
Brief emotion training improves recognition of facial emotions in chronic schizophrenia. A pilot studyHenry Silver, Craig Goodman, Gabriela Knoll, et al.
Comprehensive Psychiatry|September 24, 2005
Insight into illness in schizophreniaCraig Goodman, Gabriella Knoll, Victoria Isakov, et al.
Current Medicinal Chemistry|November 20, 2012
The role of GABA-A receptor in the synergism between SSRI and antipsychotic in schizophrenia; implications for antipsychotic modes of actionsHenry Silver, Reef Einoch, Moussa Youdim, et al.
Schizophrenia Research|April 17, 2002
Perception of happy and sad facial expressions in chronic schizophrenia: evidence for two evaluative systemsHenry Silver, Nili Shlomo, Travis Turner, et al.
The American Journal of Psychiatry|September 30, 2003
Working memory deficit as a core neuropsychological dysfunction in schizophreniaHenry Silver, Pablo Feldman, Warren Bilker, et al.
International Clinical Psychopharmacology|September 30, 2005
A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patientsHenry Silver, Craig Goodman, Victoria Isakov, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 27, 2008
Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?Henry Silver, Yael Chertkow, Orly Weinreb, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 31, 2007
Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamineYael Chertkow, Orly Weinreb, Moussa B H Youdim, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|July 7, 2009
Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophreniaYael Chertkow, Orly Weinreb, Moussa B H Youdim, et al.
The International Journal of Neuropsychopharmacology|February 26, 2010
The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatmentLena Danovich, Orly Weinreb, Moussa B H Youdim, et al.
Pageof 5